|
1.
|
|
11 p, 379.4 KB |
Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
/
Wu, Yi-Long (Guangdong Lung Cancer Institute) ;
John, Thomas (Austin Health) ;
Grohe, Christian (Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (University of California) ;
Kim, Sang-We (University of Ulsan) ;
Kato, Terufumi (Kanagawa Cancer Center) ;
Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ;
Vu, Huu Vinh (Choray Hospital) ;
Wang, Zhije (Chinese Academy of Medical Sciences) ;
Lu, Shun (Shanghai Jiao Tong University) ;
Lee, Kye Young (Konkuk University Medical Center) ;
Akewanlop, Charuwan (Siriraj Hospital) ;
Yu, Chong-Jen (National Taiwan University College of Medicine) ;
de Marinis, Filippo (European Institute of Oncology) ;
Bonanno, Laura (Istituto Oncologico Veneto) ;
Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ;
Shepherd, Frances A. (University of Toronto) ;
Zeng, Lingmin (AstraZeneca) ;
Atasoy, Ajlan (AstraZeneca) ;
Herbst, Roy S. (Yale School of Medicine) ;
Tsuboi, Masahiro (National Cancer Center Hospital East) ;
Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 -  10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433
|
|
|
2.
|
|
15 p, 1.6 MB |
A trans-omics assessment of gene-gene interaction in early-stage NSCLC
/
Chen, Jiajin (Nanjing Medical University) ;
Song, Yunjie (Department of Biostatistics. Nanjing Medical University) ;
Li, Yi (Department of Biostatistics. University of Michigan) ;
Wei, Yongyue (Nanjing Medical University) ;
Shen, Sipeng (Department of Biostatistics. Nanjing Medical University) ;
Zhao, Yang (Department of Biostatistics. Nanjing Medical University) ;
You, Dongfang (Department of Biostatistics. Nanjing Medical University) ;
Su, Li (Harvard Medical School) ;
Bjaanæs, Maria Moksnes (Department of Cancer Genetics Oslo University Hospital) ;
Karlsson, Anna (Department of Clinical Sciences. Lund University) ;
Planck, Maria (Department of Clinical Sciences. Lund University) ;
Staaf, Johan (Department of Clinical Sciences. Lund University) ;
Helland, Åslaug (Institute of Clinical Medicine. University of Oslo) ;
Esteller, M (Universitat de Barcelona) ;
Shen, Hongbing (Nanjing Medical University) ;
Christiani, David C. (Harvard Medical School) ;
Zhang, Ruyang (Nanjing Medical University) ;
Chen, Feng (State Key Laboratory of Reproductive Medicine. Nanjing Medical University)
Epigenome-wide gene-gene (G × G) interactions associated with non-small-cell lung cancer (NSCLC) survival may provide insights into molecular mechanisms and therapeutic targets. Hence, we proposed a three-step analytic strategy to identify significant and robust G × G interactions that are relevant to NSCLC survival. [...]
2023 - 10.1002/1878-0261.13345
Molecular Oncology, Vol. 17 Núm. 1 (january 2023) , p. 173-187
|
|
|
3.
|
|
10 p, 666.8 KB |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
/
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
García Gómez, Ramón (Hospital General Universitario Gregorio Marañón) ;
Diz Taín, Pilar (Hospital Universitario de León) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez Aguillo, Maite (Complejo Hospitalario de Navarra) ;
Valdivia, Javier (Hospital Universitario Virgen de las Nieves (Granada)) ;
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Peralta Muñoz, Sergio (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Gutierrez, Vanesa (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Andrade Santiago, Jesús Manuel (Hospital Virgen de la Salud (Toledo)) ;
Aparisi, Francisco (Hospital Virgen de los Lirios) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ;
Vicente Baz, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Amador, Mariluz (AstraZeneca) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear. [...]
2018 - 10.1186/s12885-018-4004-7
BMC Cancer, Vol. 18 Núm. 1 (30 2018) , p. 106
|
|
|
4.
|
|
12 p, 843.6 KB |
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy
/
Zhang, Xuanye (Sun Yat-sen University Cancer Center) ;
Tian, Dan (Guangdong Academy of Medical Sciences) ;
Chen, Yue (The Eighth Affiliated Hospital of Sun Yat-sen University) ;
Chen, Chen (Sun Yat-sen University Cancer Center) ;
He, Li-Na (Sun Yat-sen University Cancer Center) ;
Zhou, Yixin (Sun Yat-sen University Cancer Center) ;
Li, Haifeng (Sun Yat-sen University Cancer Center) ;
Lin, Zuan (Sun Yat-sen University Cancer Center) ;
Chen, Tao (Sun Yat-sen University Cancer Center) ;
Wang, Yuhong (Sun Yat-sen University Cancer Center) ;
Russo, Alessandro (A.O. Papardo) ;
Nadal, Ernest (Hospital Universitari de Bellvitge) ;
Passiglia, Francesco (S. Luigi Gonzaga Hospital) ;
Soo, Ross Andrew (National University Health System) ;
Watanabe, Satoshi (Niigata University Graduate School of Medical and Dental Sciences) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Oh, In-Jae (Hwasun Hospital) ;
Fu, Sha (Sun Yat-sen University) ;
Hong, Shaodong (Sun Yat-sen University Cancer Center) ;
Zhang, Li (Sun Yat-sen University Cancer Center) ;
Universitat Autònoma de Barcelona
The aim of this study was to evaluate the safety and survival outcomes of anti-programmed cell death (PD)-1/programmed cell death-ligand 1 (PD-L1) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) and different hepatitis B virus (HBV) infection status. [...]
2021 - 10.21037/tlcr-21-455
Translational Lung Cancer Research, Vol. 10 (july 2021) , p. 3191-3202
|
|
|
5.
|
|
13 p, 368.5 KB |
Dynamic changes in circulating tumor assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in
/
Carbonell, Caterina (Vall d'Hebron Institut d'Oncologia) ;
Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ;
Pardo Aranda, Nuria (Vall d'Hebron Institut d'Oncologia) ;
Callejo, Ana (Vall d'Hebron Institut d'Oncologia) ;
Iranzo, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Valdivia, Augusto (Vall d'Hebron Institut d'Oncologia) ;
Priano, Ilaria (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Lenza, Laura (Vall d'Hebron Institut d'Oncologia) ;
Soleda, Mireia (Vall d'Hebron Institut d'Oncologia) ;
Gonzalo-Ruiz, Javier (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Sansó, Miriam (Institut d'Investigació Sanitària Illes Balears) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Amat, Ramon (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) without a druggable oncogenic alteration. [...]
2023 - 10.1002/1878-0261.13409
Molecular Oncology, Vol. 17 (march 2023) , p. 779-791
|
|
|
6.
|
|
16 p, 1.6 MB |
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer : results from the Spanish early access program
/
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ;
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Palmero, Ramón (Hospital Universitari de Bellvitge) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Bayona, Cristina (Hospital General Yague (Burgos)) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
López-Brea, Marta (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Vicente, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Sánchez Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Diz Taín, Pilar (Complejo Asistencial Universitario de León) ;
Gordo, Rocío (Roche Farma. S.A.) ;
Coca, Margarita (Roche Farma. S.A.) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid))
This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive nonsmall-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38 Spanish hospitals. [...]
2022 - 10.18632/oncotarget.28244
Oncotarget, Vol. 13 Núm. 1 (2022) , p. 812-827
|
|
|
7.
|
|
15 p, 607.8 KB |
PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain : MOREL study
/
Rubio-Viqueira, Belen (Department of Medical Oncology. Quirónsalud Madrid Hospital. Pozuelo de Alarcón) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Lázaro, Martín (Hospital Álvaro Cunqueiro (Vigo)) ;
Estévez, Sergio Vázquez (Hospital Universitario Lucus Augusti (Lugo)) ;
Córdoba Ortega, Juan Felipe (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Maiques, Inmaculada Maestu (Hospital Universitari Doctor Peset (València)) ;
González, Jorge García (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Cordellat, Ana Blasco (Hospital General Universitario de Valencia) ;
Valdivia-Bautista, Javier (Hospital Universitario Virgen de las Nieves (Granada)) ;
Arenas, Carmen González (Department of Medical Oncology. Msd) ;
Sánchez Torres, José Miguel (Hospital Universitario de la Princesa (Madrid))
Aim: To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain. Methods: Multicenter, retrospective study. [...]
2021 - 10.2217/lmt-2021-0008
Lung Cancer Management, Vol. 10 Núm. 4 (december 2021) , p. LMT53
|
|
|
8.
|
|
0 p, 567.1 KB |
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : clinical and biomarker results from a phase I trial
/
Schuler, M. (German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany) ;
Berardi, R. (Università Politecnica delle Marche-Ospedali Riuniti) ;
Lim, W.-T (National Cancer Centre Singapore) ;
de Jonge, M. (Erasmus MC Cancer Center, Rotterdam) ;
Bauer, Todd M (Sarah Cannon Research Institute, and Tennessee Oncology) ;
Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Gottfried, M. (Oncology Institute of Meir Medical Center) ;
Han, J.Y (Center for Lung Cancer, National Cancer Center (Corea del Sud)) ;
Lee, D. H. (University of Ulsan College of Medicine (República de Corea)) ;
Wollner, M. (Rambam Health Care Campusm (Israel)) ;
Hong, David (MD Anderson Cancer Center (Estats Units d'Amèrica)) ;
Vogel, A. (Hannover Medical School (Alemanya)) ;
Delmonte, A. (Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori) ;
Akimov, Mikhail (Novartis Pharma (Siïssa)) ;
Ghebremariam, S. (Oncology Global Development-BDM) ;
Cui, X. (Novartis Institutes for Biomedical Research) ;
Nwana, N. (Oncology Precision Medicine) ;
Giovannini, M. (Novartis Pharmaceuticals Corporation(Estats Units d'Amèrica)) ;
Kim, T. M. (Seoul National University Hospital)
Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%-4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer, the best biomarker strategy for the enrichment of a susceptible patient population still remains to be defined. [...]
2020 - 10.1016/j.annonc.2020.03.293
Annals of oncology, Vol. 31 (march 2020) , p. 789-797
|
|
|
9.
|
|
20 p, 1.9 MB |
Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types
/
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gutiérrez-Chamorro, Lucía (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Gómez, Maica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García Vidal, Edurne (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Romeo, Margarita (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Morán, Teresa (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Layos, Laura (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Pérez-Roca, Laia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Riveira-Muñoz, Eva (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Fernández, Pedro Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesía, Ricard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ballana, Ester (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ample evidence exists connecting dNTP pool dysregulation to cancer and genomic instability. SAMHD1, the unique dNTP triphosphohydrolase described in humans, has been proposed to play a key role in hematological cancers, although its value in advanced solid tumors has not yet been explored. [...]
2022 - 10.20944/preprints202201.0141.v1
Cancers, Vol. 14 Núm. 3 (january 2022)
|
|
|
10.
|
|
9 p, 733.9 KB |
FDG-PET parameters predicting mediastinal malignancy in lung cancer
/
Serra Fortuny, M. (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Gallego, Miguel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Berna, Lluís (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Montón, Concepción (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Vigil Giménez, Laura (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias) ;
Masdeu, María José (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Fernández-Villar, A. (Complexo Hospitalario Universitario de Vigo) ;
Botana-Rial, M (Complexo Hospitalario Universitario de Vigo) ;
Cordovilla, Rosa (Complejo Asistencial de Salamanca) ;
García-Luján, Ricardo (Hospital Universitario 12 de Octubre (Madrid)) ;
Cases Viedma, Enrique (Hospital Universitari i Politècnic La Fe (València)) ;
Monsó, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Staging of mediastinal lymph nodes in non-small cell lung cancer (NSCLC) is mandatory. The maximum Standard Uptake Value (SUVmax) obtained using F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is the best non-invasive technique available for this evaluation, but its performance varies from center to center. [...]
2016 - 10.1186/s12890-016-0338-6
BMC Pulmonary Medicine, Vol. 16 (december 2016)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
